Epidemiology and Risk Factors of Osteosarcoma
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Osteosarcoma is a rare tumor diagnosed at any age; however younger age is a common risk factor. In addition, multiple factors are believed to contribute to higher rates of osteosarcoma, particularly race and gender. Although diagnosed worldwide, osteosarcoma is found to be more prevalent in Africa with high numbers of cases reported in Nigeria, Uganda, and Sudan. Additionally, higher rates are detected in African Americans, suggesting a genetic predisposition linked to race. This review focuses on identifying high risk factors of osteosarcoma with an emphasis on sarcoma epidemiology and risk factors in African countries.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2008, National Cancer Institute, Bethesda, MD
Howlader, N. (2011) · Medical Entomology and Zoology · Cited by 2,612
A System for the Surgical Staging of Musculoskeletal Sarcoma
ENNEKING, W. F., SPANIER, S. S., & GOODMAN, M. A. (1980) · Clinical Orthopaedics and Related Research · doi:10.1097/00003086-198011000-00013 · Cited by 2,500
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · Cancer · doi:10.1002/cncr.24121 · Cited by 2,199
Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995
US Department of Health and Human Services; National Cancer Institute (1999) · PsycEXTRA Dataset · doi:10.1037/e407432005-001 · Cited by 1,947 · cited 1×
“In two consecutive studies conducted by the National Cancer Institute SEER Program, higher annual rates of osteosarcoma in children and young adolescents were found in African American populations, while lower rates were present among Caucasian Americans, based on data published for the years 1975–1995 (44).”
BackgroundThe Epidemiology of Osteosarcoma
Ottaviani, G., & Jaffe, N. (2009) · Cancer Treatment and Research · doi:10.1007/978-1-4419-0284-9_1 · Cited by 1,786 · cited 3×
“The overall 5-year survival rate for osteosarcoma is 70% (4,14), which varies depending on the type of pathology as follows: chondroblastic 54%, fibroblastic 73%, and telangiectatic 59% (4).”
BackgroundInfluentialThe international incidence of childhood cancer
Parkin, D. M., Stiller, C. A., Draper, G. J., & Bieber, C. A. (1988) · International Journal of Cancer · doi:10.1002/ijc.2910420408 · Cited by 1,022
Mirabello, L., Troisi, R. J., & Savage, S. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24320 · Cited by 791 · cited 12×
“It appears that juvenile osteosarcoma is more often diagnosed in South Europe, Africa, Asia, South America, and the Pacific Islands, while late age of tumor onset is more prevalent in Northern Europe, US, and Australia (2).”
BackgroundInfluentialRecurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma
Chen, X., Bahrami, A., Pappo, A., Easton, J., Dalton, J., Hedlund, E., Ellison, D., Shurtleff, S., Wu, G., Wei, L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.03.003 · Cited by 752
Mining the Wnt pathway for cancer therapeutics
Barker, N., & Clevers, H. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2154 · Cited by 743 · cited 1×
“However, genetic and 86 epigenetic changes in osteosarcoma cells imply their primitive origin (18-20).”
BackgroundTrends in childhood cancer incidence in the U.S. (1992–2004)
Linabery, A. M., & Ross, J. A. (2008) · Cancer · doi:10.1002/cncr.23169 · Cited by 643
Sarcoma Derived from Cultured Mesenchymal Stem Cells
Tolar, J., Nauta, A. J., Osborn, M. J., Panoskaltsis Mortari, A., McElmurry, R. T., Bell, S., Xia, L., Zhou, N., Riddle, M., Schroeder, T. M., et al. (2007) · Stem Cells · doi:10.1634/stemcells.2005-0620 · Cited by 639 · cited 1×
“Spontaneous transformation of MSCs is shown to promote formation of osteosarcomas in animal models (26,27).”
BackgroundBleyer, A., O’Leary, M., Barr, R. D., & Ries, L. A. G. (2006) · Cited by 619
Steliarova-Foucher, E., Stiller, C., Kaatsch, P., Berrino, F., Coebergh, J.-W., Lacour, B., & Perkin, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17550-8 · Cited by 566 · cited 2×
“5 cases/million population/year) (2,54,58), more variations (1.”
ResultSecond primary neoplasms in patients with retinoblastoma
Draper, G. J., Sanders, B. M., & Kingston, J. E. (1986) · British Journal of Cancer · doi:10.1038/bjc.1986.110 · Cited by 554 · cited 1×
“Studies have identified several genetic risk markers, including hereditary retinoblastoma (Rb) (67,68), Rothmund–Thomson syndrome (70,71), and Li Fraumeni syndrome (72).”
BackgroundOsteosarcoma (Osteogenic sarcoma)
Picci, P. (2007) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-2-6 · Cited by 505 · cited 1×
“Osteoid is commonly found in osteosarcoma, suggesting that osteoblasts can be involved in the tumor development (17).”
BackgroundRadiation-induced sarcoma of bone
Arlen, M., Higinbotham, N. L., Huvos, A. G., Marcove, R. C., Miller, T., & Shah, I. C. (1971) · Cancer · doi:10.1002/1097-0142(1971)28:5<1087::aid-cncr2820280502>3.0.co;2-f · Cited by 483 · cited 1×
“(91), who showed that residents of areas with radiation ranging from 1,200 rads/few weeks to 24,000 rads/2 years were more likely to develop osteosarcoma.”
Background(2007) · Garner and Klintworth's Pathobiology of Ocular Disease (Part B) · doi:10.1201/9781420093919-41 · Cited by 477
Prognostic factors in osteosarcoma: a critical review.
Davis, A. M., Bell, R. S., & Goodwin, P. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.2.423 · Cited by 424 · cited 1×
“It appears that patients from lower socioeconomic groups have 210 higher incidence rates of osteosarcoma and mortality (69).”
BackgroundReview of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 395 · cited 1×
“Osteosarcoma is a primary bone tumor, characterized by deposition of an immature osteoid matrix (1).”
BackgroundOsteosarcoma: Anatomic and Histologic Variants
Klein, M. J., & Siegal, G. P. (2006) · American Journal of Clinical Pathology · doi:10.1309/uc6kqhld9lv2kenn · Cited by 386 · cited 2×
“In accordance with findings reported in previous studies, the authors also confirmed the higher male to female ratio and younger age of patients (4,28,54).”
BackgroundResultWalkley, C. R., Qudsi, R., Sankaran, V. G., Perry, J. A., Gostissa, M., Roth, S. I., Rodda, S. J., Snay, E., Dunning, P., Fahey, F. H., et al. (2008) · Genes & Development · doi:10.1101/gad.1656808 · Cited by 373 · cited 1×
“Combined mutations in Rb and p53 show synergistic tumorigenic properties (79,81,82).”
BackgroundWang, L. L., Gannavarapu, A., Kozinetz, C. A., Levy, M. L., Lewis, R. A., Chintagumpala, M. M., Ruiz-Maldanado, R., Contreras-Ruiz, J., Cunniff, C., Erickson, R. P., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.669 · Cited by 338 · cited 1×
“Studies have identified several genetic risk markers, including hereditary retinoblastoma (Rb) (67,68), Rothmund–Thomson syndrome (70,71), and Li Fraumeni syndrome (72).”
BackgroundOsteosarcoma treatment: state of the art
Ta, H. T., Dass, C. R., Choong, P. F. M., & Dunstan, D. E. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9186-7 · Cited by 314 · cited 1×
“Treatment usually concentrates on surgery to remove the tumor and metastasis, often in combination with chemotherapy (7).”
BackgroundStiller, C. A., Bielack, S. S., Jundt, G., & Steliarova-Foucher, E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.015 · Cited by 283
Mohseny, A. B., Szuhai, K., Romeo, S., Buddingh, E. P., Briaire‐de Bruijn, I., de Jong, D., van Pel, M., Cleton‐Jansen, A., & Hogendoorn, P. C. (2009) · The Journal of Pathology · doi:10.1002/path.2603 · Cited by 269 · cited 1×
“Spontaneous transformation of MSCs is shown to promote formation of osteosarcomas in animal models (26,27).”
BackgroundMetastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage
Berman, S. D., Calo, E., Landman, A. S., Danielian, P. S., Miller, E. S., West, J. C., Fonhoue, B. D., Caron, A., Bronson, R., Bouxsein, M. L., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805462105 · Cited by 266 · cited 1×
“Combined mutations in Rb and p53 show synergistic tumorigenic properties (79,81,82).”
BackgroundAge-specific Fluoride Exposure in Drinking Water and Osteosarcoma (United States)
Bassin, E. B., Wypij, D., Davis, R. B., & Mittleman, M. A. (2006) · Cancer Causes & Control · doi:10.1007/s10552-005-0500-6 · Cited by 249
Fifty years of cancer incidence: CI5 I–IX
Parkin, D. M., Ferlay, J., Curado, M., Bray, F., Edwards, B., Shin, H., & Forman, D. (2010) · International Journal of Cancer · doi:10.1002/ijc.25517 · Cited by 242
Modeling Familial Cancer with Induced Pluripotent Stem Cells
Lee, D.-F., Su, J., Kim, H. S., Chang, B., Papatsenko, D., Zhao, R., Yuan, Y., Gingold, J., Xia, W., Darr, H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.045 · Cited by 224 · cited 1×
“Supporters of the osteoblast origin of sarcoma argue that osteoblasts, obtained from osteosarcoma patients, and not MSCs, maintain in vitro and in vivo tumorigenesis, thus playing a role in the pathogenesis of osteosarcoma (22).”
BackgroundFrequency and structure of p53 rearrangements in human osteosarcoma.
Miller, C. W., Aslo, A., Tsay, C., Slamon, D. J., Ishizaki, K., Toguchida, J., Yamamuro, T., Lampkin, B. C., & Koeffler, H. P. (1990) · PubMed · Cited by 214
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Savage, S. A., Mirabello, L., Wang, Z., Gastier-Foster, J. M., Gorlick, R., Khanna, C., Flanagan, A. M., Tirabosco, R., Andrulis, I. L., Wunder, J. S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2645 · Cited by 202 · cited 1×
“It appears that osteosarcoma is associated with a rapid genotype modification, complicating the identification of potential therapeutic targets (83,84).”
BackgroundErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
Onda, M., Matsuda, S., Higaki, S., Iijima, T., Fukushima, J.-I., Yokokura, A., Kojima, T., Horiuchi, H., Kurokawa, T., & Yamamoto, T. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960101)77:1<71::aid-cncr13>3.0.co;2-5 · Cited by 201 · cited 1×
“Nevertheless, a variety of macromolecular biomarkers with potential clinical implications have been identified including ErbB-2 (85, 86), cathepsin D (87), FBXW7 (88), and miR-421 (89).”
BackgroundLoss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.
Feugeas, O., Guriec, N., Babin-Boilletot, A., Marcellin, L., Simon, P., Babin, S., Thyss, A., Hofman, P., Terrier, P., Kalifa, C., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.467 · Cited by 199 · cited 1×
“Mutations in the Rb gene have a strong association with predispositions to osteosarcoma (73–75), where the loss of heterogeneity in the Rb gene could indicate unfavorable disease outcome (76).”
BackgroundDedifferentiated Chondrosarcoma: The Role of Chemotherapy with Updated Outcomes
Dickey, I. D., Rose, P. S., Fuchs, B., Wold, L. E., Okuno, S. H., Sim, F. H., & Scully, S. P. (2004) · The Journal of Bone and Joint Surgery-American Volume · doi:10.2106/00004623-200411000-00008 · Cited by 194 · cited 1×
“However, highgrade lesions (3 and 4) have a higher incidence of metastasis and are characterized by mitosis, prominent nucleoli, and pleomorphism (13).”
BackgroundLi, H., Fan, X., Kovi, R. C., Jo, Y., Moquin, B., Konz, R., Stoicov, C., Kurt-Jones, E., Grossman, S. R., Lyle, S., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2665 · Cited by 194 · cited 1×
“The malignant transformation of MSCs is accompanied by accumulation of chromosomal instability and various mutations (28,29).”
BackgroundOverholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193
Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood
Le Vu, B., de Vathaire, F., Shamsaldin, A., Hawkins, M. M., Grimaud, E., Hardiman, C., Diallo, I., Vassal, G., Bessa, E., Campbell, S., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980729)77:3<370::aid-ijc11>3.0.co;2-c · Cited by 193
Alterations of thep53, Rb andMDM2 genes in osteosarcoms
Miller, C. W., Aslo, A., Won, A., Tan, M., Lampkin, B., & Koefflar, H. P. (1996) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01213553 · Cited by 190 · cited 1×
“Combined mutations in Rb and p53 show synergistic tumorigenic properties (79,81,82).”
BackgroundPutnam, J. B., Roth, J. A., Wesley, M. N., Johnston, M. R., & Rosenberg, S. A. (1983) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(10)60679-0 · Cited by 180 · cited 1×
“However, there is evidence suggesting that resection of pulmonary metastases improves the survival of these patients (34,35).”
BackgroundHuang, X., Zhao, J., Bai, J., Shen, H. M., Zhang, B., Deng, L., Sun, C., Liu, Y., Zhang, J., & Zheng, J. (2019) · Journal of bone oncology · doi:10.1016/j.jbo.2019.100230 · Cited by 179 · cited 1×
“In contrast, other studies demonstrate that chemotherapy has limited effect on the prognosis of osteosarcoma outcome in patients with lung metastasis (36).”
ResultMason, N. J., Gnanandarajah, J. S., Engiles, J. B., Gray, F., Laughlin, D., Gaurnier-Hausser, A., Wallecha, A., Huebner, M., & Paterson, Y. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0088 · Cited by 178
Of mice and men: divergent risks of teriparatide-induced osteosarcoma
Subbiah, V., Madsen, V. S., Raymond, A. K., Benjamin, R. S., & Ludwig, J. A. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1004-0 · Cited by 177 · cited 1×
“Accordingly, treatment using teriparatide, a parathyroid hormone peptide, was suggested to increase the risk of radiationinduced osteosarcoma (93).”
BackgroundStature and malignant tumors of bone in childhood and adolescence
Fraumeni, J. F. (1967) · Cancer · doi:10.1002/1097-0142(196706)20:6<967::aid-cncr2820200606>3.0.co;2-p · Cited by 150 · cited 1×
“The earliest observation of positive correlation between patient’s height and risk of osteosarcoma was published by Fraumeni in the 60s (61) and was later confirmed by multiple studies (62,64,65).”
BackgroundModeling sarcomagenesis using multipotent mesenchymal stem cells
Rodríguez, R., Rubio, R., & Menéndez, P. R. (2011) · Cell Research · doi:10.1038/cr.2011.157 · Cited by 149
Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review
Daw, N. C., Chou, A. J., Jaffe, N., Rao, B. N., Billups, C. A., Rodriguez-Galindo, C., Meyers, P. A., & Huh, W. W. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.585 · Cited by 149 · cited 1×
“Patients with lung metastasis have a higher risk of tumor relapse and fatal outcome (39,40).”
BackgroundNotch Activation as a Driver of Osteogenic Sarcoma
Tao, J., Jiang, M.-M., Jiang, L., Salvo, J. S., Zeng, H.-C., Dawson, B., Bertin, T. K., Rao, P. H., Chen, R., Donehower, L. A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.023 · Cited by 134 · cited 1×
“Supporting this notion, activation of the intracellular domain of Notch1 in transgenic mice promotes immature osteoblast proliferation and induces osteosarcomagenesis (31).”
BackgroundHigh-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study
Fagioli, F., Aglietta, M., Tienghi, A., Ferrari, S., Brach del Prever, A., Vassallo, E., Palmero, A., Biasin, E., Bacci, G., Picci, P., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.081 · Cited by 133 · cited 1×
“Major setbacks of chemotherapy are based on low tumor cell sensitivity to the treatment and subsequent side effects (37,38).”
BackgroundStature of young people with malignant bone tumors
Cotterill, S. J., Wright, C. M., Pearce, M. S., & Craft, A. W. (2004) · Pediatric Blood & Cancer · doi:10.1002/pbc.10437 · Cited by 130
Comparison ofp53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma
Gokgoz, N., Wunder, J. S., Mousses, S., Eskandarian, S., Bell, R. S., & Andrulis, I. L. (2001) · Cancer · doi:10.1002/1097-0142(20011015)92:8<2181::aid-cncr1561>3.0.co;2-3 · Cited by 125
Update on the Epidemiology of Paget's Disease of Bone
Cooper, C., Harvey, N. C., Dennison, E. M., & van Staa, T. P. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.06s201 · Cited by 124 · cited 1×
“High prevalence of the disease is documented in the United Kingdom, Australia, and North America, with a lower frequency present in Asia and the Middle East (47,48).”
BackgroundHeight at diagnosis and birth-weight as risk factors for osteosarcoma
Mirabello, L., Pfeiffer, R., Murphy, G., Daw, N. C., Patiño-Garcia, A., Troisi, R. J., Hoover, R. N., Douglass, C., Schüz, J., Craft, A. W., et al. (2011) · Cancer Causes & Control · doi:10.1007/s10552-011-9763-2 · Cited by 116 · cited 1×
“Meta-analysis demonstrated that “taller-than-average” and “very tall” individuals are at an increased risk of developing osteosarcoma (66).”
BackgroundErbB2 expression is correlated with increased survival of patients with osteosarcoma
Akatsuka, T., Wada, T., Kokai, Y., Kawaguchi, S., Isu, K., Yamashiro, K., Yamashita, T., Sawada, N., Yamawaki, S., & Ishii, S. (2002) · Cancer · doi:10.1002/cncr.10360 · Cited by 112 · cited 1×
“Nevertheless, a variety of macromolecular biomarkers with potential clinical implications have been identified including ErbB-2 (85, 86), cathepsin D (87), FBXW7 (88), and miR-421 (89).”
BackgroundMesenchymal stem cell transformation and sarcoma genesis
Xiao, W., Mohseny, A. B., Hogendoorn, P. C. W., & Cleton-Jansen, A.-M. (2013) · Clinical Sarcoma Research · doi:10.1186/2045-3329-3-10 · Cited by 103
Osteosarcoma – conventional treatment vs. gene therapy
Tan, M. L., Choong, P., & Dass, C. R. (2009) · Cancer Biology & Therapy · doi:10.4161/cbt.8.2.7385 · Cited by 99 · cited 1×
“Other chemical risk factors include methylcholanthrene and chromium salts (96), beryllium oxide (97), zinc beryllium silicate (98), asbestos, and aniline dyes (99).”
BackgroundClinicopathologic Features of Osteosarcoma in Patients With Rothmund-Thomson Syndrome
Hicks, J. M., Roth, J. R., Kozinetz, C. A., & Wang, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.4558 · Cited by 92 · cited 1×
“Studies have identified several genetic risk markers, including hereditary retinoblastoma (Rb) (67,68), Rothmund–Thomson syndrome (70,71), and Li Fraumeni syndrome (72).”
BackgroundHeight as a Risk Factor for Osteosarcoma
Longhi, A., Pasini, A., Cicognani, A., Baronio, F., Pellacani, A., Baldini, N., & Bacci, G. (2005) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000169251.57611.8e · Cited by 90 · cited 2×
“(64) showed a strong correlation between height and osteosarcoma diagnosis in growing individuals.”
BackgroundShimizu, T., Tanaka, T., Iso, T., Matsui, H., Ooyama, Y., Kawai‐Kowase, K., Arai, M., & Kurabayashi, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175786 · Cited by 90 · cited 1×
“Another important feature of these cells is their ability to differentiate into multiple cell types including osteoblasts (21).”
BackgroundGrowth and development and other risk factors for osteosarcoma in children and young adults
Gelberg, K. H., Fitzgerald, E., Hwang, S. E., & Dubrow, R. (1997) · International Journal of Epidemiology · doi:10.1093/ije/26.2.272 · Cited by 89 · cited 1×
“The pathogenesis of osteosarcoma remains largely unknown; however, correlation between bone growth during childhood/puberty and tumor risk diagnosis suggest that growth factors could play a role in the onset of the disease (15,16).”
BackgroundAbsence of the p53 tumor suppressor gene promotes osteogenesis in mesenchymal stem cells
Tataria, M., Quarto, N., Longaker, M. T., & Sylvester, K. G. (2006) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2005.12.001 · Cited by 85
A significant proportion of patients with osteosarcoma may belong to Li-Fraumeni cancer families
Porter, D. E., Holden, S., Steel, C., Bb, C., Wallace, M., & Reid, R. (1992) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.74b6.1447251 · Cited by 75 · cited 1×
“Studies have identified several genetic risk markers, including hereditary retinoblastoma (Rb) (67,68), Rothmund–Thomson syndrome (70,71), and Li Fraumeni syndrome (72).”
BackgroundThe pharmacogenomics of osteosarcoma
Serra, M., & Hattinger, C. M. (2016) · The Pharmacogenomics Journal · doi:10.1038/tpj.2016.45 · Cited by 72
Wnt signaling activation and WIF-1 silencing in nasopharyngeal cancer cell lines
Lin, Y., You, L., Xu, Z., He, B., Mikami, I., Thung, E., Chou, J. C., Kuchenbecker, K. M., Kim, J. H., Raz, D. J., et al. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.220 · Cited by 65
Ahmed, G., Zamzam, M., Kamel, A., Ahmed, S., Salama, A., Zaki, I., Kamal, N., & Elshafiey, M. M. (2018) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2018.06.019 · Cited by 64 · cited 1×
“The survival rate of osteosarcoma patients with lung metastases remains low, even when metastases are surgically removed (33).”
BackgroundmiR-421 is a diagnostic and prognostic marker in patients with osteosarcoma
Zhou, S., Wang, B., Hu, J. X., Zhou, Y., Jiang, M., Wu, M., Qin, L., & Yang, X. (2016) · Tumor Biology · doi:10.1007/s13277-015-4578-5 · Cited by 62 · cited 1×
“Nevertheless, a variety of macromolecular biomarkers with potential clinical implications have been identified including ErbB-2 (85, 86), cathepsin D (87), FBXW7 (88), and miR-421 (89).”
BackgroundRuza, E., Sotillo, E., maga, L. S. U., Azcona, C., & Patiño‐García, A. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200310000-00007 · Cited by 59
Primary bone cancer incidence in black and white residents of New York state
Polednak, A. P. (1985) · Cancer · doi:10.1002/1097-0142(19850615)55:12<2883::aid-cncr2820551231>3.0.co;2-q · Cited by 58 · cited 1×
“Similar trends persisted in older age groups, with a higher rate of osteosarcoma diagnosis reported in African Americans as compared to Caucasians (46).”
ResultBone tumours in Cameroon: incidence, demography and histopathology
Bahebeck, J., Atangana, R., Eyenga, V. C., Pisoh, A., Sando, Z., & Hoffmeyer, P. J. (2003) · International Orthopaedics · doi:10.1007/s00264-003-0480-7 · Cited by 57 · cited 2×
“The authors suggested that the high incidence rate of osteosarcoma in young patients could be explained by the larger proportion of young people in the population, where 56% of Cameroonian citizens are children or teenagers, and only 4% are elderly (56).”
BackgroundGemoll, T., Epping, F., Heinrich, L., Fritzsche, B., Roblick, U. J., Szymczak, S., Hartwig, S., Depping, R., Bruch, H., Thorns, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4140 · Cited by 56 · cited 1×
“Nevertheless, a variety of macromolecular biomarkers with potential clinical implications have been identified including ErbB-2 (85, 86), cathepsin D (87), FBXW7 (88), and miR-421 (89).”
BackgroundMatrix‐Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis
Zandueta, C., Ormazabal, C., Perurena, N., Martínez-Canarias, S., Zalacaín, M., San-Julián, M., Grigoriadis, A. E., Valencia, K., Campos-Laborie, F. J., Rivas, J. D. L., et al. (2016) · The Journal of Pathology · doi:10.1002/path.4740 · Cited by 51 · cited 1×
“Patients with lung metastasis have a higher risk of tumor relapse and fatal outcome (39,40).”
BackgroundWang, J.-Y., Wu, P.-K., Chen, P. C.-H., Lee, C.-W., Chen, W.-M., & Hung, S.-C. (2017) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0226 · Cited by 49 · cited 1×
“Additionally, the Rb1 gene deletion in MSCs causes overexpression of cMYC, which could promote the osteosarcoma-like properties and express osteosarcoma markers CD99, ALP, osteonectin, and osteocalcin (30).”
BackgroundThe epidemiology of bone cancer in 0 - 39 year olds in northern England, 1981 - 2002
Eyre, R., Feltbower, R. G., James, P. W., Blakey, K., Mubwandarikwa, E., Forman, D., McKinney, P. A., Pearce, M. S., & McNally, R. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-357 · Cited by 48
The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Deshpande, A., & Hinds, P. W. (2006) · Current Molecular Medicine · doi:10.2174/1566524010606070809 · Cited by 43
Tumours of bone and cartilage.
Kungu, A. (1978) · PubMed · Cited by 42
Paget’s disease of bone: a review
Colina, M., Corte, R. L., Leonardis, F. D., & Trotta, F. (2008) · Rheumatology International · doi:10.1007/s00296-008-0640-6 · Cited by 39 · cited 1×
“High prevalence of the disease is documented in the United Kingdom, Australia, and North America, with a lower frequency present in Asia and the Middle East (47,48).”
BackgroundGandhi, D., Naoghare, P. K., Bafana, A., Krishnamurthi, K., & Sivanesan, S. (2016) · Biological Trace Element Research · doi:10.1007/s12011-016-0756-6 · Cited by 30 · cited 1×
“(95), which suggested that fluoride-induced oxidative and inflammatory stress contribute to the pathogenesis of osteosarcoma.”
BackgroundHereditary Retinoblastoma: Host Resistance and Second Primary Tumors 2 3
Matsunaga, E. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.1.47 · Cited by 30
Thomas, L. E., Mautner, V., Cooper, D. N., & Upadhyaya, M. (2012) · Human Genomics · doi:10.1186/1479-7364-6-18 · Cited by 26
Hong, C. R., Kang, H. J., Kim, M. S., Ju, H. Y., Lee, J. W., Kim, H., Kim, H., Park, S.-H., Park, K. D., Park, J. D., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.145 · Cited by 19 · cited 1×
“Major setbacks of chemotherapy are based on low tumor cell sensitivity to the treatment and subsequent side effects (37,38).”
BackgroundAdult mortality in sub-Saharan Africa using 2001—2009 census data: does estimation method matter?
Odimegwu, C. O., Chisumpa, V. H., & Somefun, O. D. (2018) · Genus · doi:10.1186/s41118-017-0025-3 · Cited by 11
Cited by
Naringenin: A potential flavonoid phytochemical for cancer therapy
Motallebi, M., Bhia, M., Rajani, H. F., Bhia, I., Tabarraei, H., Mohammadkhani, N., Pereira-Silva, M., Kasaii, M. S., Nouri-Majd, S., Mueller, A.-L., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120752 · Cited by 328
Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017
Cole, S., Gianferante, D. M., Zhu, B., & Mirabello, L. (2022) · Cancer · doi:10.1002/cncr.34163 · Cited by 277
Tharakan, S., Raja, I., Pietraru, A., Sarecha, E., Gresita, A., Petcu, E., Ilyas, A., & Hadjiargyrou, M. (2023) · Gels · doi:10.3390/gels9040274 · Cited by 18
“Additionally, exposure to radiation is a risk factor for developing osteosarcoma [1].”
Background
Metadata
- Authors
- Sadykova, L. R., Ntekim, A. I., Muyangwa-Semenova, M., Rutland, C. S., Jeyapalan, J. N., Blatt, N., & Rizvanov, A. A.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2020-05-27
- Volume
- 38
- Issue
- 5
- Pages
- 259-269
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W3025357838
- Cited by
- 237
- References
- 79
- FWCI
- 15.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.